Matthew Szot
2023
In 2023, Matthew Szot earned a total compensation of $844.9K as Chief Financial Officer at Cadrenal Therapeutics, a 135% increase compared to previous year.
Compensation breakdown
| Bonus | $184,053 |
|---|---|
| Salary | $377,180 |
| Stock Awards | $250,000 |
| Other | $33,657 |
| Total | $844,890 |
Szot received $377.2K in salary, accounting for 45% of the total pay in 2023.
Szot also received $184.1K in bonus, $250K in stock awards and $33.7K in other compensation.
Rankings
In 2023, Matthew Szot's compensation ranked 1,403rd out of 3,006 executives tracked by ExecPay. In other words, Szot earned more than 53.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,403 out of 3,006 | 53rd |
Division Manufacturing | 836 out of 1,650 | 49th |
Major group Chemicals And Allied Products | 549 out of 918 | 40th |
Industry group Drugs | 536 out of 881 | 39th |
Industry Pharmaceutical Preparations | 375 out of 637 | 41st |
Source: SEC filing on June 11, 2024.
Szot's colleagues
We found two more compensation records of executives who worked with Matthew Szot at Cadrenal Therapeutics in 2023.